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Cardiac failure is the most common cardiovascular manifestation 
in urban Africa.[1] Dilated cardiomyopathy (DCM), defined as left 
ventri cular (LV) dilatation and systolic dysfunction, is a major cause 
of heart failure in adults between the third and fourth decades of 
life.[1-3] It is the leading cause for heart transplantation world-
wide.[3] Although population-based data on the burden of DCM in 
sub-Saharan Africa are lacking, it is reported to account for up to 
48% of patients hospitalised with cardiac failure. Idiopathic dilated 
cardiomyopathy (IDCM) was the second most common form of 
cardiomyopathy after hypertensive cardiomyopathy in the Heart of 
Soweto Study Cohort.[4-6] 
IDCM, a form of DCM without an identifiable cause, can be 
diagnosed after exclusion of secondary causes and other primary 
cardiomyopathies. Secondary causes include untreated hypertension, 
myocarditis triggered by infection, coronary artery disease, valvular 
heart disease, congenital heart disease, autoimmune disease, 
metabolic factors, alcohol abuse and nutritional deficiencies.[1,4] 
The other primary cardiomyopathies, which are classified according 
to morphofunctional phenotype, include hypertrophic obstructive 
cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), 
arrhythmogenic right ventricular cardiomyopathy (ARVC) and LV 
non-compaction cardiomyopathy (LVNCC).[7] Genetic conditions 
with dilated cardiomyopathy as a presenting feature include the 
muscular dystrophies (Duchenne and Becker muscular dystrophy, 
as well as their carrier states, Emery-Dreifuss muscular dystrophy 
and limb-girdle muscular dystrophy), hereditary haemochromatosis, 
Friedreich’s ataxia, Barth syndrome, mitochondrial myopathies and 
numerous inborn errors of metabolism.[8,9] Up to half of all cases of 
IDCM are believed to be hereditary or familial.[1,2,4,10] Timeous referral 
of DCM patients for management of cardiac failure, arrhythmias 
and life-saving interventions such as cardiac transplantation is of 
the utmost importance. The abovementioned factors highlight the 
significance of identifying patients with familial DCM and screening 
their relatives to identify at-risk presymptomatic family members.[1] 
Patients with DCM most commonly present with decompensated 
cardiac failure.[10] Other manifestations may include arrhythmias, 
sudden cardiac death and, less commonly, a thromboembolic 
event.[8,11,12] Most patients with DCM are diagnosed when they 
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Background. Familial disease is implicated in 20 - 50% of cases of idiopathic dilated cardiomyopathy (IDCM) worldwide. The contribution 
of familial factors to IDCM in the Johannesburg area, South Africa, is unknown. 
Objectives. To describe the demographic details of patients with IDCM who presented at Charlotte Maxeke Johannesburg Academic Hospital 
(CMJAH), and to determine if there is evidence of familial disease through family history assessment and clinical screening of relatives. 
Methods. This was a single-centre, cohort study performed at a quaternary care centre at CMJAH. Fifty unrelated probands diagnosed with 
IDCM and available first- and second-degree relatives were included in the study. A three-generation family pedigree was drawn up for all 
50 probands. The pedigrees were analysed to identify the presence or absence of familial disease and categorised as positive, intermediate, 
negative or unreliable according to the family history obtained. From the 50 proband cases, there were 21 family members available for 
screening for features of IDCM. Eighty-two family members (55 first-degree and 27 second-degree relatives) were screened clinically. 
Screening included a personal history, full physical examination, electrocardiogram (ECG) and echocardiogram. 
Results. The mean age at diagnosis of IDCM in the probands was 41.7 (standard deviation (SD) 12.4) years. The majority of probands were 
males (n=38; 76%). Of 50 pedigrees analysed, 14 (28%) were positive and likely to be indicative of familial dilated cardiomyopathy (DCM), 
and 9 (18%) patients were at intermediate risk of familial disease. Eighty-two asymptomatic family members were screened, with a median 
age of 33 (range 11 - 76) years. No asymptomatic family members were identified with features of DCM or presymptomatic DCM. Eleven of 
the 21 families screened had relatives with possible presymptomatic DCM identified by abnormalities on the echocardiogram in 3 families 
(14.3%) (4 individuals; all first-degree relatives of the index case) or identified on the basis of a conduction defect (an arrhythmia or first-/
second-/third-degree heart block) in 8 families (72.7%) (11 individuals; 9 first-degree and 2 second-degree relatives). 
Conclusions. Screening for IDCM should include a three-generation family history and clinical screening of all first-degree family 
members. As IDCM has an age-related penetrance, at-risk family members should receive follow-up for screening to assess symptoms and 
signs of IDCM. Genetic testing would potentially identify family members at high risk, who would benefit from screening; this might be a 
less expensive option. 
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become symptomatic; however, presymptomatic affected individuals 
can be detected during specialist cardiovascular examination by 
identifying echocardiographic signs of LV enlargement, a decreased 
ejection fraction and/or fractional shortening, wall motion 
abnormalities and atrial enlargement, and electrocardiographic 
features, including a primary, secondary or tertiary atrioventricular 
block, a left or right bundle branch block, abnormal QRS patterns 
(including left or right axis deviation), premature ventricular or atrial 
contractions, atrial fibrillation or flutter and ventricular arrhythmias/
tachycardias.[8] This so-called presymptomatic stage may persist 
for months to years without the onset of symptoms.[8] Identifying 
presymptomatic individuals can provide an opportunity for invoking 
lifestyle changes and allow for pharmacological therapy to be initiated 
in the earlier stages of the course of the disease, with the aim of limiting 
the progression of cardiac failure and controlling arrhyth mia.[10,13] Diagnosis 
of DCM requires specialist investigations such as echocardiography, 
which is mostly limited to tertiary medical centres.[4] 
 Familial DCM is a monogenic disorder with mutations identified 
in >40 genes. It is mostly inherited in an autosomal dominant manner, 
although autosomal recessive, X-linked and mitochondrial patterns 
of inheritance have been described.[2,14] Autosomal dominant familial 
DCM is characterised by incomplete and/or variable expressivity with 
regard to age of onset, severity of symptoms and risk of complications.[14] 
Advances in genetic testing have changed the approach to genetic 
diagnoses of the cardiomyopathies. Familial DCM is the most 
genetically heterogeneous of the cardio myopathies.[15] A major role-
player in familial DCM is the TTN gene, encoding the protein titin. 
Approximately 20 - 25% of familial DCM patients have a truncating 
mutation in this gene.[15] Truncating mutations in the TTN gene 
have also been found in patients with peripartum cardiomyopathy, 
which shares clinical features with IDCM and may be part of the 
spectrum of familial DCM.[16,17] In some patients with familial 
DCM, the findings of cardiac conduction defects may point to a 
mutation in certain genes such as LMNA and SCN5A. Identifying the 
genetic mutation may alter specific management. For example, it is 
recommended that individuals with LMNA mutations benefit from 
early implantable cardioverter defibrillators (ICDs).[18,19] Targeted 
gene panels using next-generation sequencing (NGS) are commonly 
used in developed countries and have a diagnostic yield of 30 - 35%.[9,19,20] 
The causative mutations in South African (SA) patients have not been 
investigated or identified to date. 
Objectives
The aim of this article was to describe the demographic details of 
patients with IDCM in the Johannesburg area and to determine, 
by family history assessment and clinical screening of relatives, if 
evidence of familial disease exists.
Methods
Study design and study population
This was a single-centre study performed at the Department of 
Cardiology, Charlotte Maxeke Johannesburg Academic Hospital 
(CMJAH). 
Each proband diagnosed with IDCM had to fulfil all of the following 
criteria: (i) clinical evidence of cardiac failure with LV dilatation; 
(ii) LV ejection fraction (LVEF) of <50% on echocardiography; and 
(iii) exclusion of common secondary causes of DCM. All probands 
were offered clinical screening for family members; however, only 21 of 
the probands’ family members were available for screening (Fig. 1).
All study participants had undergone a comprehensive clinical 
assessment, including a three- to four-generation family pedigree, 
personal medical history, clinical examination (performed by a 
cardiologist (NT)), electrocardiogram (ECG) and echocardiogram. 
Data collected for each study participant included ethnicity, 
gender, current age, age at which the proband was diagnosed 
with IDCM, clinical cardiovascular examination detail, ECG and 
echocardiogram findings. Further relevant family history included 
ischaemic heart disease, cerebrovascular disease that possibly 
reflected a thromboembolic event, hypertension or other relevant 
genetic conditions, including muscular dystrophies. Based on 
family history, a pedigree was constructed and analysed. Each 
family was classified as either positive for familial DCM, having 
an intermediate-risk or negative family history or unknown status. 
The criteria are set out in Table 1. Patient accounts of cardiovascular 
 
Participants (N=162)
Participants included 
in the analysis (n=132)
Probands with IDCM (n=50) 
(pedigrees analysed (n=50))
First-degree relatives 
screened by physical 
examination, echocardiogram 
and ECG (n=55)
Second-degree relatives 
screened by physical examination, 
echocardiogram and ECG (n=27) 
From 21 
families screened
Exclusion of 9 non-related participants 
and 21 distant relatives 
(third-degree relatives or greater)
Fig. 1. Flow chart of study population. (IDCM = idiopathic dilated cardiomyopathy; ECG = electrocardiogram.)
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diagnoses and their aetiologies are not always reliable, cannot 
necessarily be proven and need to be interpreted with caution.[8] 
When an individual with IDCM gives a history of family members 
with heart failure, sudden death, heart attacks, arrhythmias, 
pacemakers or heart failure symptoms, such a history should not 
be ignored, but should raise suspicion of familial cardiac disease, 
including familial DCM, especially when the relatives are young.[8] 
This was the rationale for the criteria used to classify the family 
pedigrees during analysis.
Screening of asymptomatic family members included a physical 
examination, ECG and echocardiography. Echocardiography 
assessment included LV internal diameter in diastole (LVIDd) 
and LVEF. ECG screening was performed for cardiac conduction 
abnormalities, including a primary, secondary or tertiary atrio-
ventricular block, a left or right bundle branch block, abnormal QRS 
patterns (including left or right axis deviation), premature ventricular 
or atrial contractions, atrial fibrillation or flutter and ventricular 
arrhythmias/tachycardias. The echocardiogram and ECG findings 
were interpreted with assistance from NT.
Based on the abovementioned results, each asymptomatic family 
member was categorised into one the following groups: (i) features 
of DCM; (ii) features of presymptomatic DCM; (iii) possible 
presymptomatic DCM and cardiac conduction abnormality; and (iv) no 
features of DCM. Criteria for categorisation of family members based 
on screening are set out in Table 2.
Ethical approval
The study was approved by the University of the Witwatersrand 
Human Research Ethics Committee (ref. no. HREC M150467). 
The study participants were recruited from the co-author’s (NT) 
study entitled ‘Genetics of idiopathic dilated cardiomyopathy in 
Johannesburg’, and included the first 50 probands diagnosed with 
IDCM and available family members seen over an 18-month period 
(July 2015 - February 2017). Written informed consent was obtained 
by the co-authors for the utilisation of relevant clinical data. 
Statistical analysis
Statistical analysis was performed using TIBCO Statistica 13.3.0 
(TIBCO Software Inc., USA). Descriptive statistics of the study 
cohort were applied as either means with standard deviations (SDs) 
if normally distributed or medians with interquartile ranges if not 
normally distributed. Frequency analysis was performed for discrete 
variables and represented as percentages, with 95% confidence 
intervals (CIs) where appropriate. A t-test was performed to assess 
for significant age differences between male and female probands. 
A p-value of <0.05 was considered statistically significant.
Results
Index case demographics
Fifty probands were included in the study cohort. Of these, 38 (76%) 
were males. The mean age at diagnosis of IDCM was 41.7 (SD 12.4) 
years for all probands, 42.5 (SD 11.24) years for males and 39.3 
(SD 15.85) years for females, with no statistically significant differ-
ences in the ages of men and women (p=0.5). The racial distribution 
comprised 43 (86%) black Africans, 3 (6%) whites, 3 (6%) of mixed 
ancestry and 1 (2%) of Indian descent. 
Pedigree analysis
As per the criteria set out in Table 1, 14 (28.0%) of the 50 pedigrees 
analysed had a positive family history of familial DCM, 9 (18%) an 
intermediate-risk family history, 12 (24%) a negative family history 
and 15 (30%) an unreliable family history. Positive or intermediate 
family pedigrees were therefore seen in 23 (46%) families. A summary 
of the pedigree analysis can be seen in Fig. 2.           
Family member analysis
Fifty-five first-degree relatives were screened, including 25 (45.5%) 
males and 30 (54.5%) females, with a median age of 38 (range 11 - 
76) years. Twenty-seven second-degree relatives were screened, 
including 11 (41%) males and 16 (59%) females, with a median age 
of 22 (range 12 - 72) years.
Table 1. Family pedigree analysis – criteria for classification 
Family pedigree analysis Criteria 
Positive for familial DCM A family member of the index case with at least one of the following findings: 
Diagnosis of DCM
History of peripartum cardiomyopathy
History of unexplained cardiac death (<50 years of age)
Family member required a pacemaker for a cardiac arrhythmia
Family member received a cardiac transplantation for cardiac failure
Intermediate-risk family history Family member >50 years of age with a history of cardiac death or of unexplained cardiac failure
Negative family history No history of DCM, unexplained cardiac death, cardiac failure and of family members with 
symptoms of cardiac failure
Unknown status Unknown or unreliable family history due to lack of information 
DCM = dilated cardiomyopathy.
Table 2. Categorisation of family members based on ECG and echocardiogram screening
Categories ECG and echocardiogram findings
Features of DCM Family members with an LVEF <50% and an LVIDd >95th centile (>56 mm) for age and sex
Features of presymptomatic DCM Family members with an LVEF <50% and an LVIDd >95th centile (>56 mm) for age and sex
Possible presymptomatic DCM Family members with an LVEF >50%, an LVIDd <95th centile (<56 mm) for age and sex, and/or an ECG 
abnormality (arrhythmia, sinus node dysfunction, first-/second-/third-degree heart block, bundle branch 
block, abnormal QRS pattern)
No features of DCM Family members with an LVEF >50%, an LVIDd <95th centile (<56 mm) for age and sex and a normal ECG
ECG = electrocardiogram; DCM = dilated cardiomyopathy; LVEF = left ventricular ejection fraction; LVIDd = left ventricular internal diameter in diastole.
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According to the criteria stated in the abovementioned methods 
section, none of the 82 asymptomatic family members included in the 
screening analysis had identifiable features of DCM. One first-degree 
family member who attended a screening had already been diagnosed 
with IDCM and was symptomatic. None of the 82 asymptomatic 
family members were identified with presymptomatic DCM. 
Eleven families with members with possible presymptomatic 
DCM were identified. In 3 (14%) families, 4 first-degree relatives 
of the probands had abnormalities detected on echocardiography. 
In 8 (38%) families, 11 individuals were identified with possible 
presymptomatic DCM, based on finding a cardiac conduction defect 
(either a sinus node dysfunction or a first-/second-/third-degree 
heart block). Nine (81.8%) of the 11 individuals were first-degree 
relatives and 2 (18.2%) were second-degree relatives. No identifiable 
features of DCM were detected in 10 (48%) families screened. 
The screening results for the asymptomatic family members are 
summarised in Table 3.
From the 15 individuals with possible presymptomatic DCM, 4 (26.7%) 
were from 4 families with a positive family history, 6 (40%) were 
identified from 3 families with an intermediate family history, 3 (20%) 
were identified in 2 families with a negative history and 2 (13.3%) 
were identified in 2 families with an unknown family history. 
Ten (66.7%) individuals with possible presymptomatic DCM were 
therefore identified in high-risk families (i.e. those with positive and 
intermediate-risk family histories).
Discussion
Pedigree analysis
IDCM is associated with a high mortality and is an important 
contributor to the burden of disease in Africa.[1] This study shows that 
patients with IDCM seen at CMJAH are diagnosed at a similar age as 
those reported elsewhere, with an average age of diagnosis of 41 years. 
Our study also shows that a greater percentage of males appear to be 
affected than females, with 76% of index cases being males. This is in 
accordance with the literature, where males are almost twice as likely 
to be affected.[1,4] 
A positive family history was found in 14 (28%) of the 50 family 
pedigrees analysed, which is similar to findings reported by Ntusi et al.,[5] 
Fig. 2. Results of family pedigree analysis. (DCM = dilated cardiomyopathy; SCD = sudden cardiac death; PPCM = peripartum cardiomyopathy; 
CCF = congestive cardiac failure.)
Positive family history identied by: 
• Family history of DCM (n=4) 
• Family history of SCD (<50 years of age) (n=8) 
• Family history of arrhythmia (n=2) 
• Family history of PPCM (n=0) 
• Family history of cardiac transplant (n=0) 
 Intermediate-risk family history identied by: 
• Family history of SCD (>50 years of age) (n=7) 
• Family history of unexplained CCF (n=2) 
Positive family history (n=14; 28%)
Intermediate-risk family history (n=9; 18%)
Negative family history (n=12; 24%)
Unreliable/unknown family history (n=15; 30%) 
Pedigrees analysed 
(n=50)
Table 3. Results of screening of asymptomatic family members*
Features of DCM
Families, n (%) 
(n=21)
First-degree relatives, 
n (%) (n=55)
Second-degree 
relatives, n (%) (n=27)
Features of DCM 0 1 (2) (diagnosis 
of IDCM prior to 
study)
0
Features of presymptomatic DCM 0 0 0
Possible presymptomatic DCM with echocardiogram anomaly 3 (14) 4 (7) 0
Possible presymptomatic DCM with cardiac conduction abnormality 8 (38) 9 (16) 2 (7)
No features of DCM 10 (48) 41 (75) 25 (93)
DCM = dilated cardiomyopathy; IDCM = idiopathic dilated cardiomyopathy.
*A total of 21 families attended screening, including 82 asymptomatic family members, 55 first-degree and 27 second-degree relatives.
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where familial disease was found in 26.6% of patients with IDCM by 
family pedigree analysis in Cape Town. The pedigrees with positive 
and intermediate family histories appeared most consistent with an 
autosomal dominant pattern of inheritance: 13 of 14 (93%) positive 
family histories were clearly consistent with an autosomal dominant 
inheritance pattern and only 1 of 14 (7%) had a possible autosomal 
recessive or X-linked inheritance pattern – a family with male non-
identical twins affected with IDCM. This may also be explained by a 
germline mutation in a parent or autosomal dominant disease with 
reduced penetrance. The interpretation of the family histories may 
be further complicated by non-penetrance, age-related penetrance 
and variable expressivity, which may be features of familial DCM and 
appeared to be evident in the family pedigrees analysed. In only 4 of 
14 (26%) cases with a positive family history did the proband give a 
history of a relative with a known diagnosis of IDCM.
In 2 of 9 (22%) intermediate-risk families, there was a history 
of unexplained cardiac failure, emphasising the importance of a 
diagnosis of the cause of cardiac failure and exclusion of secondary 
causes and other primary cardiomyopathies. The remainder of 
the intermediate-risk families (7 of 9; 77%) had unexplained death 
believed to be due to a cardiac event in family members >50 years 
of age. This may illustrate the possible age-related penetrance and 
variable expressivity of familial DCM in individuals who died; 
however, aetiologies of these deaths are unknown and may also be 
due to non-cardiac causes or cardiac causes unrelated to familial 
DCM. A high index of suspicion is needed if there is a family history 
of any individual with symptoms of cardiac failure, arrhythmias or 
unexplained sudden death.[8] Symptoms of typical cardiac failure are 
nonspecific, which is a limitation to the validity and accuracy of a 
family history, further emphasising the importance of an objective 
evaluation of LV function, particularly in first-degree relatives of 
probands with IDCM.
Twelve (24%) of the probands who were classified as having a 
negative family history were able to give a detailed family history 
where there was no history of any relatives with cardiac disease or 
unexplained cardiac deaths, and the proband appeared to be the 
first and only case of IDCM in the pedigree. This occurrence of a 
negative family history appears to be much lower than that reported 
by Ntusi et al.,[5] where 73.4% of their cases of IDCM appeared to be 
non-familial. This can be explained by our classification of the family 
pedigrees, which included intermediate-risk family histories and 
unknown or unreliable family histories, resulting in a lower negative 
family history.
An unknown or unreliable family history was found in 15 (30%) 
cases. This was mostly explained by probands not having recent 
contact with relatives who resided in different provinces or countries, 
not having knowledge of the cause of death of relatives, difficulty in 
accessing death certificates of relatives with unexpected or unknown 
death, and a general lack of knowledge of their relatives and 
family histories. These factors make a family pedigree as a primary 
assessment tool somewhat insensitive. A positive family history is 
significant and requires follow-up, but a negative family history does 
not exclude familial DCM.
Screening analysis
In a single family, 1 individual (a sibling of the index case) who 
attended screening was symptomatic and had been previously 
diagnosed with IDCM. No family members screened fulfilled 
criteria for features of DCM or presymptomatic DCM. This may 
be explained by the disease penetrance typically occurring in adult 
life, while relatively young adults (median 33 (range 11 - 76) years) 
were screened, who may not yet have developed detectable cardiac 
abnormalities. 
In 11 of 21 (52.4%) families, criteria for possible presymptomatic 
DCM were identified. The condition was identified by an abnormality 
on the echocardiogram in 3 (14.3%) families – all first-degree relatives 
of the index case. The echocardiographic abnormalities identified 
included an increased LVIDd in 3 individuals (2 from the same 
family) and a reduced LVEF in 1 individual. None of the 27 second-
degree relatives had abnormalities detected on echocardiography, 
showing that such screening appears more beneficial for first-degree 
relatives, as might be predicted.
Eight of 21 (38.1%) families with possible presymptomatic DCM 
were identified based on a cardiac conduction defect (either a sinus 
dysfunction or first-/second-/third-degree heart block) in a family 
member. Due to limited specificity of cardiac failure symptoms, we 
opted to screen all available family members to objectively confirm 
or exclude DCM. This led to a high number of second-degree 
relatives being screened. Screening should ideally be limited to 
first-degree relatives; screening of second-degree relatives is usually 
only performed when there are anxious relatives or in families with 
a particularly lethal or penetrant phenotype.[8,19] Ten of 15 (66.7%) 
individuals with possible presymptomatic DCM were found in 
the positive and intermediate-risk family pedigrees, showing the 
importance of family history in identifying relatives for screening.
SA patients suffering from IDCM often live in resource-limited 
environments, where there may be a delay in diagnosis. When a 
patient is diagnosed with IDCM, there is a good opportunity for 
screening family members and patient education regarding the 
possibility of the condition being familial. 
An evaluation of patients with IDCM should include investigating 
whether the disease is familial.[19] A cascade approach to screening of 
first-degree relatives should be used including:
• taking a three-generation family history, keeping in mind the lack 
of specificity of cardiac failure symptoms and the possibility of 
unknown and unreliable family histories
• clinical screening for cardiomyopathy in first-degree relatives 
through clinical examination, an echocardiogram and an ECG to 
determine if any relatives are affected.[2,9] 
The landscape of genetic testing is changing with the advent of NGS 
technology. As whole exome or genome genetic testing becomes more 
accessible, cardiac clinicians will increasingly request genetic testing 
for probands and family members. The role of the geneticist will be 
for pre- and post-test counselling, patient education and interpreting 
results of genetic testing. Specialty centres will need to be established 
for these patients. Genetic testing for the cardiomyopathies, including 
IDCM, is not available for the majority of patients in SA who make 
use of State genetic services, but limited testing is available in the 
private sector. Genetic testing may be offered to individuals with 
sporadic IDCM, familial DCM or peripartum and pregnancy-
associated cardiomyopathy.[9] The rationale for identifying a causal 
mutation would be to allow mutation-specific cascade screening of 
family members. This will determine which family members require/
do not require ongoing surveillance.[2,15] When a DCM mutation 
is identified in an asymptomatic individual, annual screening by 
physical examination, echocardiography and ECG is recommended 
to commence from childhood. When a familial mutation has not 
been identified or testing has not been performed, first-degree 
relatives of an individual with IDCM should be screened every 
3 - 5 years from childhood.[5,18,19] Limitations to genetic testing would 
include the high cost and possible low detection rate of pathogenic 
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mutations. Mutations may be population specific, and distinguishing 
clearly pathogenic mutations from benign polymorphisms may be a 
challenge, as the genetics of IDCM has not been fully investigated and 
established in African, including SA, patients. These genetic studies 
need to be done, and once local mutation profiles are established, may 
provide an effective way to identify presymptomatic at-risk family 
members.
Study limitations
Our study has some limitations. Patients are often uncertain of their 
family history and uninformed regarding the cause of death of their 
relatives, which is a major limitation to interpreting a family history. 
Furthermore, reviewing hospital records of deceased relatives is a 
challenge when the relatives died in peripheral hospitals. The small 
number of first-degree relatives screened is a limitation, as most 
guidelines advocate for screening of first-degree relatives only in 
IDCM. In our setting, this was difficult, as many relatives lived far 
away, some even in neighbouring countries, and were unable to 
attend screening. This would possibly also have affected the accuracy 
of the family histories, as many individuals had not had recent 
and frequent contact with family members. The small number of 
probands included in the study possibly influenced the capacity to 
detect significant findings.
Conclusions
Our research has shown that familial disease is common in patients 
presenting with IDCM at CMJAH. Forty-sixty percent of probands 
had a positive or intermediate-risk family history. Family pedigrees 
were almost exclusively consistent with an autosomal dominant 
inheritance pattern, showing variable expressivity and age-related 
penetrance, with probands giving family histories of cardiac disease 
and deaths in individuals ˂50 years and ≥50 years of age. Screening 
for familial disease with history alone is insufficient, as an unreliable 
and unknown family history was found in 30% of cases. 
We have also shown the benefit of screening first-degree family 
members. No asymptomatic family members screened by ECG 
and echocardiogram were found to have features of DCM or 
presymptomatic DCM. Relatives were identified in 11 of 21 (52.4%) 
families with possible presymptomatic DCM with cardiac conduction 
abnormality. Co-ordinating the family screening to include first-
degree relatives appears to be appropriate and is best undertaken with 
the assistance of a professional trained in genetics, who can interpret 
complicated family histories and pedigrees.
These findings have an impact on the clinical evaluation of patients 
with IDCM at CMJAH. The evaluation of a proband should include a 
thorough three-generation family history, genetic counselling for the 
family, and 3 - 5-yearly clinical screening by physical examination, 
echocardiogram and ECG of first-degree relatives. Although the 
age of commencement of screening is uncertain, guidelines suggest 
screening from childhood, especially in cases of early onset and 
aggressive phenotypes. This represents a significant challenge and 
cost in our current healthcare system, particularly if first-degree 
relatives live significant distances from centres with cardiology 
services. Future research should include identifying the causative 
genetic mutations that contribute significantly to IDCM in SA and 
establishing locally appropriate genetic testing. Patients presenting 
with IDCM could then be given accurate genetic counselling and 
testing, and screening could be rationalised to high-risk family 
members who are carriers of a predisposing mutation.
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